1.38
-0.09(-6.12%)
Currency In USD
| Previous Close | 1.47 |
| Open | 1.52 |
| Day High | 1.55 |
| Day Low | 1.36 |
| 52-Week High | 8.94 |
| 52-Week Low | 0.92 |
| Volume | 969,581 |
| Average Volume | 409,305 |
| Market Cap | 34.1M |
| PE | -0.63 |
| EPS | -2.18 |
| Moving Average 50 Days | 1.34 |
| Moving Average 200 Days | 2.36 |
| Change | -0.09 |
If you invested $1000 in Medicus Pharma Ltd. Common Stock (MDCX) since IPO date, it would be worth $647.32 as of March 04, 2026 at a share price of $1.45. Whereas If you bought $1000 worth of Medicus Pharma Ltd. Common Stock (MDCX) shares 1 year ago, it would be worth $500 as of March 04, 2026 at a share price of $1.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Medicus Pharma To Participate in the 38th Annual Roth Conference
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readinessPHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Medic
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
GlobeNewswire Inc.
Feb 10, 2026 12:30 PM GMT
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
GlobeNewswire Inc.
Jan 22, 2026 12:30 PM GMT
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr